Astellas Pharma Inc: Adenocarcinoma trials

The registry lists 16 Adenocarcinoma studies with Astellas Pharma Inc as lead sponsor. 8 are open to participants now and 2 have results posted.

Phase 1 5Phase 2 3Phase 3 4Phase 4 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE)Not yet recruitingNCT07858500
• A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric CancerNot yet recruitingNCT07829757Phase 4
• A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric CancerRecruitingNCT07673887Phase 3
• A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsRecruitingNCT07488676Phase 1/2
• A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.RecruitingNCT06902545
• A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerRecruitingNCT06901531Phase 3
• Early Access Program for ZolbetuximabAvailableNCT06048081
• A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerRecruitingNCT05365581Phase 1
• A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).Active, not recruitingNCT03653507Phase 3Results posted
• A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.Active, not recruitingNCT03504397Phase 3Results posted
• A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaCompletedNCT04086758Phase 1
• A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) AdenocarcinomaCompletedNCT03528629Not applicable
• Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric CancerCompletedNCT01671774Phase 1
• Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric CancerCompletedNCT01630083Phase 2
• Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic CancerCompletedNCT01010945Phase 1
• Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) CancerCompletedNCT00073502Phase 2